GO:0006579 amino-acid betaine catabolic process: Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006579 describes the biochemical breakdown of amino-acid betaines, primarily glycine betaine, into smaller metabolites such as dimethylglycine and glycine.
• Betaine catabolism is a major source of methyl groups for the methionine cycle and is tightly linked to choline and one-carbon metabolism.
• Key enzymes include betaine-homocysteine S-methyltransferase (BHMT) and dimethylglycine dehydrogenase (DMGDH), which catalyze sequential demethylation steps.
• Genetic variation in methylenetetrahydrofolate reductase (MTHFR) can influence betaine concentrations and the response to betaine supplementation.
• Disrupted betaine catabolism has been associated with remethylation disorders, cardiovascular disease, and altered lipid metabolism.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of betaine catabolic genes in health and disease.
Description
Amino-acid betaine catabolic process (GO:0006579) is the set of chemical reactions and pathways that break down betaines, which are N-trimethyl derivatives of amino acids, into simpler molecules. The most studied betaine in humans is glycine betaine, a zwitterionic compound that serves as an organic osmolyte and a methyl donor. This catabolic process is essential for maintaining cellular methyl balance and for recycling homocysteine to methionine, thereby supporting methylation reactions that regulate gene expression and protein function. Researchers study GO:0006579 because its dysregulation has been implicated in inborn errors of metabolism, cardiovascular disease, and cancer, and because it intersects with choline, folate, and sulfur amino acid pathways. Understanding the enzymes and transporters involved in betaine catabolism provides a foundation for developing targeted nutritional and pharmacological interventions.
amino-acid betaine catabolic process At A Glance
| GO ID | GO:0006579 |
|---|---|
| GO term | amino-acid betaine catabolic process |
| Ontology | biological_process |
| Synonym | betaine breakdown; betaine catabolic process; betaine catabolism; betaine degradation |
| Major function | Breakdown of N-trimethyl amino acid derivatives (e.g., glycine betaine) to generate methyl donors and smaller metabolites |
| Key enzymes | BHMT, DMGDH, SARDH, and related methyltransferases and dehydrogenases |
| Pathway context | Choline and one-carbon metabolism; methionine cycle; sulfur amino acid metabolism |
| Subcellular location | Cytoplasm and mitochondria |
| Related diseases | Remethylation disorders, hyperhomocysteinemia, cardiovascular disease, fatty liver disease |
What Is GO:0006579?
According to the Gene Ontology, amino-acid betaine catabolic process (GO:0006579) refers to the chemical reactions and pathways resulting in the breakdown of any betaine, the N-trimethyl derivative of an amino acid. In practice, this includes the demethylation of glycine betaine to dimethylglycine and subsequently to sarcosine and glycine, as well as the transfer of methyl groups to homocysteine to form methionine. The term is a biological process and is synonymous with betaine breakdown, betaine catabolic process, betaine catabolism, and betaine degradation.
Why Is amino-acid betaine catabolic process Important in Cell Biology?
Amino-acid betaine catabolism is critical for cellular methyl homeostasis and for the detoxification of homocysteine, a risk factor for cardiovascular and neurological disorders. The pathway also contributes to lipid metabolism and energy balance, as betaine-derived methyl groups are used in phosphatidylcholine synthesis and very-low-density lipoprotein assembly. Moreover, betaine catabolism influences epigenetic regulation through the production of S-adenosylmethionine, the universal methyl donor for DNA and histone methylation. Consequently, this process is a focal point for research on metabolic syndrome, birth defects, and cancer, and it offers actionable targets for nutritional and pharmacological modulation.
• Maintains methionine cycle flux by remethylating homocysteine to methionine.
• Provides methyl groups for DNA and histone methylation, impacting epigenetic gene regulation.
• Supports lipid metabolism and lipoprotein assembly, influencing cardiovascular risk.
• Protects cells against osmotic stress as part of the betaine osmolyte system.
• Dysregulation is linked to remethylation disorders and hyperhomocysteinemia.
• Genetic variants in MTHFR modulate betaine status and supplementation outcomes.
• Betaine catabolism intersects with sulfur amino acid metabolism and redox balance.
• Altered betaine levels are observed in obesity and metabolic syndrome.
• Enzymes of this pathway are potential biomarkers for metabolic and cardiovascular diseases.
• CRISPR screens can identify novel regulators of betaine catabolism for therapeutic targeting.
What Happens During amino-acid betaine catabolic process?
Uptake and Transport of Betaine
In simple terms: Betaine must first enter the cell before it can be broken down.
Betaine is transported across the plasma membrane by amino acid secondary transporters, which couple its movement to ion gradients. These transporters ensure that betaine is available for catabolic enzymes in the cytoplasm and mitochondria. The expression and activity of these transporters can influence the overall rate of betaine catabolism and the cellular response to osmotic stress.
Demethylation of Glycine Betaine to Dimethylglycine
In simple terms: The first breakdown step removes one methyl group from betaine.
Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the transfer of a methyl group from glycine betaine to homocysteine, producing methionine and dimethylglycine. This reaction is a major route for homocysteine remethylation in the liver and kidney and links betaine catabolism directly to the methionine cycle. The activity of BHMT is regulated by substrate availability and hormonal signals, and its dysfunction can lead to elevated homocysteine.
Oxidation of Dimethylglycine to Sarcosine and Glycine
In simple terms: Further demethylation steps convert dimethylglycine into sarcosine and then glycine.
Dimethylglycine dehydrogenase (DMGDH) and sarcosine dehydrogenase (SARDH) sequentially oxidize dimethylglycine to sarcosine and then to glycine, generating reducing equivalents in the form of FADH2 and 5,10-methylenetetrahydrofolate. These reactions occur in the mitochondrial matrix and feed one-carbon units into the folate pool, supporting nucleotide synthesis and methylation reactions. Deficiencies in these enzymes can cause accumulation of dimethylglycine and sarcosine, which are associated with metabolic disorders.
Integration with One-Carbon and Folate Metabolism
In simple terms: The breakdown products feed into the folate cycle to support methylation.
The one-carbon units generated from betaine catabolism enter the folate cycle as 5,10-methylenetetrahydrofolate, which can be reduced to 5-methyltetrahydrofolate for homocysteine remethylation by methionine synthase. This interconnection ensures that betaine catabolism contributes to the methylation potential of the cell, influencing epigenetic marks and gene expression. Genetic variants in MTHFR, a key folate cycle enzyme, can alter the reliance on betaine as a methyl donor.
Regulation by Substrate Availability and Hormones
In simple terms: The speed of betaine breakdown depends on how much betaine is available and on hormonal signals.
Betaine catabolism is regulated by dietary intake of betaine and choline, as well as by hormones such as insulin and glucagon that modulate enzyme expression. The pathway is also responsive to osmotic stress, which increases betaine synthesis and accumulation in some tissues. These regulatory mechanisms ensure that methyl group supply matches cellular demand for methylation and osmoprotection.
Key Genes Involved in GO:0006579 amino-acid betaine catabolic process
The following genes encode enzymes and transporters that directly participate in or regulate amino-acid betaine catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BHMT | Catalyzes betaine-dependent remethylation of homocysteine to methionine | Target for hyperhomocysteinemia and cardiovascular disease studies |
| DMGDH | Oxidizes dimethylglycine to sarcosine in mitochondria | Biomarker for dimethylglycine dehydrogenase deficiency |
| SARDH | Oxidizes sarcosine to glycine, generating one-carbon units | Linked to sarcosinemia and metabolic disorders |
| MTHFR | Reduces 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate | Common polymorphisms affect betaine requirements and supplementation outcomes |
| MTR | Methionine synthase; remethylates homocysteine using 5-methyltetrahydrofolate | Interacts with betaine pathway in one-carbon metabolism |
| CHDH | Choline dehydrogenase; converts choline to betaine | Provides substrate for betaine catabolism |
| SLC6A12 | Betaine/GABA transporter; mediates cellular uptake of betaine | Influences intracellular betaine availability |
| SLC6A6 | Taurine and beta-alanine transporter; may transport betaine | Potential role in betaine transport in kidney |
| SLC7A5 | L-type amino acid transporter; transports large neutral amino acids | May contribute to betaine uptake in some tissues |
| SLC38A2 | Sodium-coupled neutral amino acid transporter; transports small amino acids | Candidate for betaine transport |
| SLC36A1 | Proton-coupled amino acid transporter; transports small amino acids | Possible betaine transporter in intestine |
| SLC43A1 | L-type amino acid transporter; transports branched-chain amino acids | May influence betaine availability |
| SLC16A10 | Aromatic amino acid transporter; transports tryptophan and thyroid hormones | Indirect role in amino acid homeostasis |
| SLC3A2 | Heavy chain of amino acid transporters; partners with light chains | Modulates transporter activity for betaine uptake |
| SLC1A5 | Neutral amino acid transporter; transports glutamine and others | Potential indirect effect on betaine metabolism |
| SLC7A11 | Cystine/glutamate antiporter; regulates redox balance | Cross-talk with sulfur amino acid metabolism |
| SLC25A13 | Mitochondrial aspartate/glutamate carrier; supports one-carbon metabolism | Indirect link to betaine catabolism via mitochondrial transport |
How Is amino-acid betaine catabolic process Regulated?
Amino-acid betaine catabolic process is regulated at multiple levels. Substrate availability, particularly dietary betaine and choline, directly influences flux through the pathway. Hormonal signals such as insulin and glucagon modulate the expression of BHMT and other enzymes, integrating betaine catabolism with whole-body energy status. The pathway is also subject to feedback regulation by methionine and S-adenosylmethionine, which can inhibit key enzymes to prevent excessive methyl group accumulation. Additionally, osmotic stress induces betaine synthesis and transport, indirectly affecting catabolic flux. Genetic variation in MTHFR and other one-carbon cycle genes can shift the reliance on betaine as a methyl donor, thereby altering pathway activity.
amino-acid betaine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BHMT | Hyperhomocysteinemia; cardiovascular disease | Bhmt knockout mouse; hepatocyte cell model |
| DMGDH | Dimethylglycine dehydrogenase deficiency; metabolic disorder | Dmgdh knockout mouse; patient-derived fibroblasts |
| SARDH | Sarcosinemia; neurological symptoms | Sardh knockout mouse; neuronal cell lines |
| MTHFR | Remethylation disorders; neural tube defects | Mthfr knockout mouse; lymphoblastoid cell lines |
| CHDH | Choline deficiency; fatty liver disease | Chdh knockout mouse; hepatocyte cell model |
Remethylation Disorders and Hyperhomocysteinemia
Inborn errors of remethylation, including defects in methionine synthase and methylenetetrahydrofolate reductase, can disrupt the balance between betaine catabolism and homocysteine remethylation. Patients with these disorders often present with elevated homocysteine and neurological symptoms, and betaine supplementation is used therapeutically to provide an alternative methyl donor. Understanding the catabolic pathway is essential for optimizing treatment and monitoring metabolic control.
Cardiovascular Disease and Lipid Metabolism
Betaine catabolism influences lipid metabolism by supplying methyl groups for phosphatidylcholine synthesis and lipoprotein assembly. Elevated homocysteine, a consequence of impaired betaine-dependent remethylation, is an independent risk factor for cardiovascular disease. Genetic and nutritional factors that alter betaine catabolic flux may therefore modulate cardiovascular risk.
Obesity and Metabolic Syndrome
Amino acid derivatives, including betaine, play roles in the regulation of obesity and energy homeostasis. Betaine supplementation has been shown to modulate betaine concentrations depending on MTHFR genotype, but without consistent effects on amino acid profiles in healthy active males. These findings suggest that betaine catabolism may be a determinant of inter-individual responses to nutritional interventions.
Cancer and Epigenetic Regulation
Betaine catabolism contributes to the cellular methyl pool, which is critical for DNA and histone methylation. Dysregulation of one-carbon metabolism, including betaine-dependent remethylation, can lead to aberrant epigenetic patterns that promote tumorigenesis. Targeting betaine catabolic enzymes may therefore offer novel strategies for cancer therapy, although further research is needed.
From amino-acid betaine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of BHMT alter homocysteine levels? | BHMT knockout mouse or HepG2 cells with CRISPR KO |
| How does MTHFR polymorphism affect betaine requirement? | Knock-in mouse carrying MTHFR variant or isogenic cell lines |
| Can overexpression of DMGDH reduce dimethylglycine toxicity? | DMGDH overexpression in HEK293 or primary fibroblasts |
| What is the subcellular localization of SARDH? | Tagged knock-in of SARDH with fluorescent protein in HeLa cells |
| Which genes regulate betaine catabolism in liver? | CRISPR library screening in hepatocyte cell lines |
| Does betaine supplementation rescue remethylation defects? | Patient-derived iPSCs with CRISPR correction |
How to Study the amino-acid betaine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of betaine, dimethylglycine, sarcosine, methionine | Quantifying pathway flux in cells and tissues |
| Stable isotope tracing | Methyl group transfer and metabolic fate | Determining contribution of betaine to methionine cycle |
| Enzyme activity assay | Catalytic activity of BHMT, DMGDH, SARDH | Characterizing mutant enzymes from CRISPR models |
| qRT-PCR | mRNA expression of pathway genes | Assessing transcriptional regulation |
| RNA-seq | Global gene expression changes | Identifying downstream effects of gene knockouts |
| CRISPR knockout screen | Genes required for growth under specific conditions | Discovering novel regulators of betaine catabolism |
| Western blot | Protein levels of key enzymes | Validating overexpression or knockout efficiency |
| Immunofluorescence | Subcellular localization of enzymes | Confirming mitochondrial or cytoplasmic localization |
Metabolomics and Stable Isotope Tracing
Metabolomic profiling using mass spectrometry can quantify betaine, dimethylglycine, sarcosine, and methionine to assess flux through the catabolic pathway. Stable isotope-labeled betaine (e.g., d9-betaine) allows tracing of methyl group transfer and identification of metabolic intermediates in cell and animal models. These methods are essential for validating CRISPR models and for measuring pathway activity in response to genetic or nutritional perturbations.
Enzyme Activity Assays
Enzymatic assays for BHMT, DMGDH, and SARDH measure the conversion of substrates to products using spectrophotometric or chromatographic detection. These assays can be performed on cell lysates or purified recombinant proteins to determine kinetic parameters and the impact of mutations. They are particularly useful for characterizing point mutations introduced by CRISPR.
Gene Expression Analysis
Quantitative RT-PCR and RNA-seq can measure the expression of genes involved in betaine catabolism under different conditions. This approach helps identify transcriptional regulation and splice variants that may affect enzyme function. Combining RNA-seq with CRISPR knockout models reveals downstream pathways affected by loss of specific genes.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of betaine catabolism by selecting for cells with altered growth under betaine-limited or high-homocysteine conditions. These screens generate candidate gene lists that can be validated with targeted knockouts or overexpression. Bioinformatics analysis of screening data helps prioritize pathways and networks for further study.
How CRISPR Can Be Used to Study GO:0006579 amino-acid betaine catabolic process
Knockout
CRISPR-Cas9 knockout of genes such as BHMT, DMGDH, or SARDH creates cell and animal models to study loss-of-function phenotypes in betaine catabolism. These models can reveal compensatory mechanisms, changes in metabolite levels, and effects on homocysteine remethylation. Knockout studies are essential for establishing causal roles of specific enzymes in metabolic pathways.
Point Mutation
Introducing disease-associated point mutations (e.g., in MTHFR or BHMT) using CRISPR base editing or homology-directed repair allows researchers to study the functional impact of specific variants on enzyme activity and pathway flux. Such models are valuable for understanding genetic predisposition to remethylation disorders and for testing personalized interventions.
Knock-in
Knock-in of reporter tags (e.g., GFP, FLAG) or epitope tags into endogenous loci enables real-time tracking of enzyme localization and expression without overexpression artifacts. Tagged knock-in models are particularly useful for imaging and proteomic studies of betaine catabolic enzymes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like DMGDH or BHMT can increase pathway flux and test whether enhanced catabolism protects against homocysteine toxicity or alters lipid metabolism. Overexpression models complement knockout studies by providing gain-of-function insights.
How EDITGENE Supports amino-acid betaine catabolic process Research
Researchers studying amino-acid betaine catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolite flux, disease risk, or therapeutic response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for amino-acid betaine catabolic process research.
Frequently Asked Questions About amino-acid betaine catabolic process
What is amino-acid betaine catabolic process?
It is the set of biochemical reactions that break down betaines, such as glycine betaine, into smaller metabolites like dimethylglycine and glycine, as defined by GO:0006579.
What genes are involved in amino-acid betaine catabolic process?
Key genes include BHMT, DMGDH, SARDH, MTHFR, and CHDH, which encode enzymes that catalyze or regulate the breakdown of betaine.
Why is betaine catabolism important for human health?
It supports homocysteine remethylation, methyl group supply for epigenetics, and lipid metabolism; dysregulation is linked to cardiovascular disease and remethylation disorders.
How is betaine catabolism regulated?
It is regulated by substrate availability, hormones like insulin and glucagon, feedback inhibition by methionine, and genetic variants in one-carbon cycle genes.
What diseases are associated with defects in betaine catabolism?
Remethylation disorders, hyperhomocysteinemia, cardiovascular disease, fatty liver disease, and obesity have been associated with altered betaine metabolism.
Can betaine supplementation affect betaine catabolism?
Yes, supplementation increases betaine concentrations, but the response may depend on MTHFR genotype and does not consistently alter amino acid profiles.
What model systems are used to study betaine catabolism?
Knockout mice, patient-derived fibroblasts, hepatocyte cell lines, and CRISPR-engineered isogenic cell lines are commonly used.
How can CRISPR help study amino-acid betaine catabolic process?
CRISPR enables knockout, knock-in, point mutation, and overexpression models to test the causal role of specific genes in betaine metabolism and disease.
What are the main enzymes in betaine catabolism?
BHMT, DMGDH, and SARDH are the principal enzymes that sequentially demethylate and oxidize betaine and its intermediates.
Where does betaine catabolism occur in the cell?
The initial remethylation step occurs in the cytoplasm, while subsequent oxidation steps take place in the mitochondrial matrix.
Conclusion
Amino-acid betaine catabolic process (GO:0006579) is a central metabolic pathway that links dietary betaine and choline to homocysteine remethylation, one-carbon metabolism, and epigenetic regulation. Its dysregulation contributes to remethylation disorders, cardiovascular disease, and metabolic syndrome, making it a compelling target for both basic and translational research. Advances in CRISPR genome editing now allow precise interrogation of the enzymes and transporters involved, accelerating the discovery of biomarkers and therapeutic strategies. EDITGENE's comprehensive CRISPR services empower researchers to build robust models and uncover causal mechanisms in betaine catabolism.
References
- 1. Olivieri G et al.. 2026. First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.. J Inherit Metab Dis 49(4):e70177 PMID: 42231716
- 2. Zawieja E et al.. 2024. Betaine supplementation modulates betaine concentration by methylenetetrahydrofolate reductase genotype, but has no effect on amino acid profile in healthy active males: A randomized placebo-controlled cross-over study.. Nutr Res 127:63-74 PMID: 38876040
- 3. Blachier F et al.. 2020. Sulfur-Containing Amino Acids and Lipid Metabolism.. J Nutr 150(Suppl 1):2524S-2531S PMID: 33000164
- 4. Schweikhard ES et al.. 2012. Amino acid secondary transporters: toward a common transport mechanism.. Curr Top Membr 70:1-28 PMID: 23177982
- 5. Craig SA. 2004. Betaine in human nutrition.. Am J Clin Nutr 80(3):539-49 PMID: 15321791
- 6. Zeisel S. 2017. Choline, Other Methyl-Donors and Epigenetics.. Nutrients 9(5) PMID: 28468239
- 7. Niu T et al.. 2023. Effects of exogenous glycine betaine and cycloleucine on photosynthetic capacity, amino acid composition, and hormone metabolism in Solanum melongena L.. Sci Rep 13(1):7626 PMID: 37165051
- 8. Zheng J et al.. 2021. Roles of amino acid derivatives in the regulation of obesity.. Food Funct 12(14):6214-6225 PMID: 34105579
